The EMERALD trial investigators randomly assigned 478 patients with ER+, HER2- advanced breast cancer on a 1:1 basis to receive elacestrant or physician’s choice of standard therapy, which was defined ...
In the United States, more than half of people living with HIV are now age 50 and older, which is a testament to the success of advancements such as antiretrovirals and preexposure anaphylaxis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback